Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance

CVS Health CorpTrade
iShares 3 7 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs iShares 3 7 Year Treasury Bond ETF — how do they compare? CVS Health Corp trades at $86.4 (market cap $112.29B), while iShares 3 7 Year Treasury Bond ETF trades at $113.4 (market cap $16.72B). The key difference: CVS Health Corp is far larger — about 6.7× iShares 3 7 Year Treasury Bond ETF's market cap, and CVS Health Corp pays a 3.03% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and iShares 3 7 Year Treasury Bond ETF for 43 Days on average.

CVSIEI
Market Cap
$112.29B$16.72B
Volume
7,763,6763,963,319
Sector
HealthFixed Income
52-Week High
$110.60$120.72
52-Week Low
$70.08$113.17
Typical Hold Time
83 Days43 Days
Enterprise Value
$174.64B—
Dividend Yield
3.03%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.

The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.

iShares 3 7 Year Treasury Bond ETF

IEI trades at $113.41, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though oscillators remain neutral. Recent dividend payments of $0.37-0.38 per share provide income stability. The stock faces headwinds from broader bond market volatility as Treasury yields reach multi-decade highs, impacting fixed-income related equities.

The outlook remains cautious amid persistent bond market pressures. While dividend payments offer some support, the bearish technical setup and elevated Treasury yields create near-term challenges. Investment opportunity exists for income-focused investors, but requires careful monitoring of interest rate developments and bond market stability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS

No sentiment data available yet.

IEI
0% Buy100% Sell
Avg holding period · 43 Days

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About iShares 3 7 Year Treasury Bond ETF

IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.

Read more on IEI →